SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

The Dogecoin community is abuzz with speculation over its potential integration into Elon Musk's X platform for payments, driving fervent hopes for a significant rally while others caution against market volatility.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

PEPE is experiencing strong upward momentum, with the crypto community enthusiastically discussing a "meme coin season" and its potential for significant gains, often framing it as the "alpha frog" in a broader "three frog narrative."

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending amidst widespread community discussion of a potential 'meme coin season,' with many comparing its performance to other surging meme tokens like PEPE and DOGE while a significant portion of the community expresses frustration and skepticism regarding its long-term viability.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending as the FDA granted Priority Review for AXS-05 to treat Alzheimer's disease agitation, with an April PDUFA date, fueling community optimism alongside robust sales growth for its major depressive disorder treatment, Auvelity. Investors are keenly discussing the significant market potential for its expanding neuroscience pipeline and the company's strong commercial execution, with many anticipating substantial share appreciation.

Ramaco Resources, Inc. engages in the operation and development of coal mining properties. The firm deals with metallurgical coal in central and southern West Virginia, southwestern Virginia and southwestern Pennsylvania. Its portfolio consists of Elk Creek, Berwind, RAM Mine, and Knox Creek. The company was founded by Randall W. Atkins in August 2015 and is headquartered in Lexington, KY.

Ramaco Resources Inc - Ordinary Shares - Class A

Ramaco Resources Inc

Ramaco Resources is trending due to high anticipation for the upcoming Critical Minerals Summit, with the community actively discussing potential U.S. government investment in domestic critical mineral producers and the company's unique position with its Brook Mine rare earth project, further boosted by a recent analyst upgrade despite past volatility over potential price floor policies.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is trending as its preliminary financial results highlight strong initial sales for Tonmya, prompting community discussion about the new fibromyalgia treatment's promising launch trajectory compared to other CNS drugs. Despite historical concerns regarding dilution, increasing institutional ownership and the company's significant cash reserves are driving a narrative that the stock is currently undervalued given Tonmya's commercial traction and pipeline potential.

Seeker is building a decentralized mobile ecosystem designed to challenge entrenched mobile incumbents through its TEEPin network architecture and community governance. It aims to solve the pain points of centralized app store gatekeeping, lack of developer freedom, and restricted user access to crypto applications. The vision is to create a community-owned platform with decentralized governance, no gatekeepers, direct developer-user access, and TEEPin security architecture.

Saakuru

Despite confusion around its ticker identity on some platforms, the crypto community is actively discussing a token, widely believed to be the "Seeker Solana Smartphone Token," following its new listings on major exchanges and recent airdrops to Solana phone owners. This asset is experiencing significant momentum, drawing comparisons to past Solana ecosystem pumps, while some caution about potential profit-taking and volatility.

BlockDAG

BlockDAG is trending as its community grapples with continuous, often conflicting, announcements regarding its mainnet launch and exchange listings, leading to widespread speculation and frustration over perceived delays, lost coins, and concerns about the project's overall legitimacy as a presale.

Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It develops verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin. The company was founded in April 2021 and is headquartered in Waltham, MA.

Upstream Bio Inc.

Upstream Bio is trending due to a significant market sell-off following its Phase 2 VALIANT trial results for verekitug in severe asthma. Although the drug showed strong efficacy with quarterly dosing, the community is debating an 'overreaction' because the highly anticipated biannual dosing did not meet market expectations, with many investors now viewing it as a dip-buying opportunity.

Thermo Fisher Scientific Inc. serves the scientific community through a broad offering of innovative products and services. Thermo Fisher Scientific serves customers working in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental, industrial, research and development, quality and process control settings. The company’s global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through its brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. The company continuously increases its depth of capabilities across its broad portfolio of innovative products and services and leverages its extensive global channels to address customers’ needs. The company does this through organic investments in research and development, capacity and capabilities and through acquisitions. The company’s goal is to enable its customers to be more productive in an increasingly competitive business environment, enable them to accelerate innovation, solve their challenges and advance their important work. The company’s history roots back to the year 1956 when the business was first established. Thermo Fisher Scientific was formed in 2006 from the merger of Thermo Electron and Fisher Scientific and is headquartered in Waltham, MA.

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific is generating significant buzz due to its strategic collaborations, particularly its role in Nvidia's AI-driven drug discovery initiatives, positioning it as a key 'picks and shovels' provider in the evolving life sciences landscape. The community is actively discussing its ongoing acquisitions and product innovations, from advanced diagnostics to lab equipment, which analysts see as crucial for long-term growth and market leadership. Despite some recent performance fluctuations, these moves are driving conversation around the company's resilience and future impact within the broader healthcare sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Anheuser-Busch InBev SA/NV's (BUD) Buy Rating Reaffirmed at The Goldman Sachs Group

The Goldman Sachs Group reaffirmed a "buy" rating on shares of Anheuser-Busch InBev SA/NV in a research note on Friday...

Anheuser-Busch InBev SA/NV (NYSE:BUD) Receives "Buy" Rating from Barclays

Barclays reissued a "buy" rating on shares of Anheuser-Busch InBev SA/NV in a report on Friday...

Anheuser-Busch InBev SA/NV Q4 Earnings Call Highlights

Anheuser-Busch InBev SA/NV (NYSE:BUD) executives highlighted full-year 2025 earnings results that included dollar-based EPS growth, margin expansion, and what management described as solid free cash...

Anheuser-Busch InBev SA/NV (NYSE:BUD) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Anheuser-Busch InBev SA/NV (NYSE:BUD - Get Free Report) announced its quarterly earnings results on Thursday. The consumer goods maker reported $0.95 earnings per share for the quarter, beating...

AB InBev Q4 Earnings Beat on Business Momentum, Revenues Miss

BUD tops Q4 EPS estimates on strong megabrand momentum and premiumization, but revenues miss as beer volumes dip amid weak demand and weather woes.

Anheuser-Busch InBev SA/NV (NYSE:BUD) Receives Buy Rating from Jefferies Financial Group

Jefferies Financial Group reiterated a "buy" rating on shares of Anheuser-Busch InBev SA/NV in a research report on Thursday...

Anheuser-Busch InBev SA/NV's (BUD) "Buy" Rating Reaffirmed at Royal Bank Of Canada

Royal Bank Of Canada reaffirmed a "buy" rating on shares of Anheuser-Busch InBev SA/NV in a research report on Thursday...

Anheuser-Busch InBev SA/NV (NYSE:BUD) Given Buy Rating at Sanford C. Bernstein

Sanford C. Bernstein reissued a "buy" rating on shares of Anheuser-Busch InBev SA/NV in a report on Thursday...

UBS Group Reiterates "Buy" Rating for Anheuser-Busch InBev SA/NV (NYSE:BUD)

UBS Group reiterated a "buy" rating on shares of Anheuser-Busch InBev SA/NV in a research note on Thursday...

Anheuser-Busch Inbev (BUD) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Anheuser-Busch Inbev (BUD) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Anheuser-Busch InBev SA/NV operates as a holding company, which engages in the manufacture and distribution of alcoholic and non-alcoholic beverages. It operates through the following geographical segments: North America, Middle Americas, South America, EMEA, Asia Pacific, and Global Export and Holding Companies. The company was founded on August 2, 1977 and is headquartered in Leuven, Belgium.

Anheuser-Busch InBev SA/NV - ADR

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

BUD
Anheuser-Busch InBev

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BUD News

BUDAnheuser-Busch InBev